The estimated Net Worth of Chuck Ence is at least $118 Tisíc dollars as of 29 January 2024. Chuck Ence owns over 38,970 units of Relmada Therapeutics Inc stock worth over $117,689 and over the last 5 years Chuck sold RLMD stock worth over $0.
Chuck has made over 1 trades of the Relmada Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Chuck bought 38,970 units of RLMD stock worth $150,814 on 29 January 2024.
The largest trade Chuck's ever made was buying 38,970 units of Relmada Therapeutics Inc stock on 29 January 2024 worth over $150,814. On average, Chuck trades about 3,897 units every 0 days since 2019. As of 29 January 2024 Chuck still owns at least 38,970 units of Relmada Therapeutics Inc stock.
You can see the complete history of Chuck Ence stock trades at the bottom of the page.
Chuck's mailing address filed with the SEC is C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES, FL, 33134.
Over the last 6 years, insiders at Relmada Therapeutics Inc have traded over $1,379,052 worth of Relmada Therapeutics Inc stock and bought 574,305 units worth $1,722,071 . The most active insiders traders include Sergio Traversa, Charles J Casamento a Paul Edward Kelly. On average, Relmada Therapeutics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $54,221. The most recent stock trade was executed by Sergio Traversa on 9 September 2024, trading 140,000 units of RLMD stock currently worth $394,800.
relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and
Relmada Therapeutics Inc executives and other stock owners filed with the SEC include: